Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 studyDiana Cortés‐Selva, Raluca Verona, Cuc Davis et al.|Blood|2024Cited by 60
Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC-1Diana Cortés‐Selva, Raluca Verona, Tineke Casneuf et al.|Blood|2022Cited by 46
P32 MAJESTEC-1: CORRELATIVE ANALYSES OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)Niels W.C.J. van de Donk, Raluca Verona, Diana Cortés‐Selva et al.|HemaSphere|2023Cited by 7
Longitudinal mechanisms of response, resistance and relapse to teclistamab in multiple myeloma: results from MajesTEC-1Deeksha Vishwamitra, Raluca Verona, Sheri Skerget et al.|Haematologica|2026Cited by 0